Abstract
Drugs that affect serotonergic (5-HT) neurotransmission modulate facial emotion recognition. For instance, 3,4-methylenedioxymethamphetamine (MDMA, the active constituent of ‘ecstasy’) acutely reduces fear identification in healthy humans; whereas selective 5-HT reuptake inhibitor (SSRI) antidepressants either increase or decrease fear identification, depending on whether dosing is acute or chronic. In contrast, relatively little is known about the role of dopaminergic (DA) signaling in perception of facial emotion in humans. However, patients with both schizophrenia and Parkinson’s Disease (PD), disorders characterized by increased and decreased DA function respectively, have impairments in social functioning and specifically in facial emotion processing, suggesting a role for DA neurotransmission in facial emotion recognition. These prior findings, as well as evidence about effects of DA medications on processing of emotional faces, indicate that emotion recognition may follow an inverted U-shape curve as a function of DA signaling. Introduction
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
